FDA grants orphan drug designation to LP-184 for pancreatic cancer

FDA grants orphan drug designation to LP-184 for pancreatic cancer

The FDA granted orphan drug designation to LP-184 for the treatment of pancreatic cancer.LP-184 (Lantern Pharma) is a next-generation alkylating agent designed to preferentially damage DNA in cancer cells that overexpress certain biomarkers or harbor mutations in DNA repair pathways, according to a Lantern Pharma-issued press release.The agent is in development for several targeted indications in oncology.Results of research conducted in in-vivo mouse models showed LP-184 shrunk pancreatic tumors by more than 90% over 8 weeks. Tumors in untreated mice grew by 11-fold during the same period.Read More

Share on facebook
Share on twitter
Share on linkedin